October Pharma results, Fiscal year 2021
Net profit, assets, equity and cash flow for Fiscal year 2021, against the same period a year earlier, from the published financial statements.
Net profit120 millionEGP · +35.7% vs the same period a year earlier
Total assets553 millionEGP · −8.8% vs the same period a year earlier
Shareholders' equity339 millionEGP · +33.7% vs the same period a year earlier
Operating cash flow262 millionEGP · +1125.4% vs the same period a year earlier
In short
- October Pharma's net profit for Fiscal year 2021 was about 120 million EGP, up +35.7% from 88.26 million EGP in Fiscal year 2020.
- Total assets at the end of Fiscal year 2021 were about 553 million EGP, and shareholders' equity about 339 million EGP.
- Operating cash flow for Fiscal year 2021 was positive at 262 million EGP.
Key lines against the same period a year earlier
This periodFiscal year 2020Change
Net profit120 million88.26 million+35.7%
Gross profit335 million261 million+28.4%
Total assets553 million606 million−8.8%
Total liabilities214 million352 million−39.4%
Shareholders' equity339 million254 million+33.7%
Total liabilities and equity553 million606 million−8.8%
Operating cash flow262 million21.39 million+1125.4%
Investing cash flow-21.4 million-6.98 million−206.7%
Financing cash flow-226 million-29.28 million−671.5%
Net change in cash14.86 million-14.86 million+200.0%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version.
October Pharma's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy